DE60029929D1 - VERWENDUNG VON PYRIDAZINO i4,5-(b)ö-INDOLE-1-ACETAMIDE DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR BEHANDLUNG VON DURCH PERIPHERE BENZODIAZEPINREZEPTOREN-STÖRUNGEN VERURSACHTE KRANKHEITEN - Google Patents

VERWENDUNG VON PYRIDAZINO i4,5-(b)ö-INDOLE-1-ACETAMIDE DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR BEHANDLUNG VON DURCH PERIPHERE BENZODIAZEPINREZEPTOREN-STÖRUNGEN VERURSACHTE KRANKHEITEN

Info

Publication number
DE60029929D1
DE60029929D1 DE60029929T DE60029929T DE60029929D1 DE 60029929 D1 DE60029929 D1 DE 60029929D1 DE 60029929 T DE60029929 T DE 60029929T DE 60029929 T DE60029929 T DE 60029929T DE 60029929 D1 DE60029929 D1 DE 60029929D1
Authority
DE
Germany
Prior art keywords
pyridazino
indole
medicament
manufacture
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60029929T
Other languages
English (en)
Other versions
DE60029929T2 (de
Inventor
Badia Ferzaz
Jesus Benavides
Frank Marguet
Jacques Froissant
Benoit Marabout
Yannick Evanno
Mireille Sevrin
Philip Janiak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of DE60029929D1 publication Critical patent/DE60029929D1/de
Application granted granted Critical
Publication of DE60029929T2 publication Critical patent/DE60029929T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60029929T 1999-01-26 2000-01-21 VERWENDUNG VON PYRIDAZINO i4,5-(b)ö-INDOLE-1-ACETAMIDE DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR BEHANDLUNG VON DURCH PERIPHERE BENZODIAZEPINREZEPTOREN-STÖRUNGEN VERURSACHTE KRANKHEITEN Expired - Lifetime DE60029929T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9900806 1999-01-26
FR9900806A FR2788696B1 (fr) 1999-01-26 1999-01-26 Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
PCT/FR2000/000135 WO2000044384A1 (fr) 1999-01-26 2000-01-21 UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AUX MALADIES LIEES AU DYSFONCTIONNEMENT DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES

Publications (2)

Publication Number Publication Date
DE60029929D1 true DE60029929D1 (de) 2006-09-21
DE60029929T2 DE60029929T2 (de) 2007-08-30

Family

ID=9541212

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60029929T Expired - Lifetime DE60029929T2 (de) 1999-01-26 2000-01-21 VERWENDUNG VON PYRIDAZINO i4,5-(b)ö-INDOLE-1-ACETAMIDE DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR BEHANDLUNG VON DURCH PERIPHERE BENZODIAZEPINREZEPTOREN-STÖRUNGEN VERURSACHTE KRANKHEITEN

Country Status (32)

Country Link
US (1) US6395729B1 (de)
EP (1) EP1148881B1 (de)
JP (1) JP4688295B2 (de)
KR (1) KR100694752B1 (de)
CN (1) CN100577167C (de)
AR (1) AR022413A1 (de)
AT (1) ATE335487T1 (de)
AU (1) AU764445B2 (de)
BG (1) BG65152B1 (de)
BR (1) BR0007718A (de)
CA (1) CA2360754C (de)
CO (1) CO5160242A1 (de)
CY (1) CY1106257T1 (de)
CZ (1) CZ294283B6 (de)
DE (1) DE60029929T2 (de)
DK (1) DK1148881T3 (de)
EE (1) EE04905B1 (de)
ES (1) ES2269097T3 (de)
FR (1) FR2788696B1 (de)
HK (1) HK1040905B (de)
HU (1) HU228670B1 (de)
IL (2) IL144181A0 (de)
NO (1) NO321997B1 (de)
NZ (1) NZ512981A (de)
PL (1) PL193420B1 (de)
PT (1) PT1148881E (de)
RU (1) RU2243764C2 (de)
SK (1) SK285707B6 (de)
TR (1) TR200102134T2 (de)
TW (1) TW541177B (de)
UA (1) UA70349C2 (de)
WO (1) WO2000044384A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003326B1 (ru) * 1998-12-02 2003-04-24 Пфайзер Продактс Инк. Способ лечения рака
FR2811897A1 (fr) * 2000-07-24 2002-01-25 Sanofi Synthelabo UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1- ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AU TRAITEMENT DES DYSFONCTIONNEMENTS DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES
FR2838124B1 (fr) * 2002-04-03 2004-05-28 Sanofi Synthelabo Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique
FR2876715B1 (fr) 2004-10-19 2006-12-15 Profiles Du Ct Sa Embout de protection pour ecran de glissiere de securite routiere
GT200600005A (es) * 2005-01-12 2006-08-16 Un derivado de 2-(aminocarbonilo ciclico)-indolina y una composicion farmaceutica que lo contiene
JP5483874B2 (ja) * 2005-05-05 2014-05-07 サノフィ−アベンティス・ユー・エス・エルエルシー 安定なナノ粒子処方物
KR20080061354A (ko) * 2005-08-29 2008-07-02 사노피-아벤티스 유.에스. 엘엘씨 7-클로로-Ｎ,Ｎ,5-트리메틸-4-옥소-3-페닐-3,5-디히드로-4Ｈ-피리다지노[4,5-ｂ]인돌-1-아세트아미드의 무정형 고체분산체
BRPI0615259A2 (pt) * 2005-08-29 2011-05-17 Sanofi Aventis Us Llc forma cristalina de um derivado de piridazino[4,5-b] indol
CN1946120B (zh) * 2006-10-20 2010-05-12 华为技术有限公司 实现话单关联的方法及系统
FR2918563B1 (fr) 2007-07-12 2009-12-04 Oreal Composition photoprotectrice fluide aqueuse a base d'un polymere polyamide a terminaison amide tertiaire.
FR2931064B1 (fr) 2008-05-14 2010-08-13 Oreal Composition cosmetique contenant un derive de dibenzoylmethane et un derive de pyrrolidinone; procede de photostabilisation du derive de dibenzoylmethane
CN102186854A (zh) * 2008-08-18 2011-09-14 赛诺菲-安万特美国有限责任公司 制备7-氯-N，N，5-三甲基-4-氧代-3-苯基-3，5-二氢-4H-哒嗪并[4，5-b]吲哚-1-乙酰胺的多晶型的方法
GB0818738D0 (en) * 2008-10-13 2008-11-19 Ge Healthcare Ltd Imaging neuroflammation
FR2936706B1 (fr) 2008-10-08 2010-12-17 Oreal Composition cosmetique contenant un derive de dibenzoylmethane et un compose dithiolane ; procede de photostabilisation du derive de dibenzoylmethane
EP2181717A1 (de) * 2008-10-28 2010-05-05 Sanofi-Aventis Verwendung von 7-Chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-B]indol-1-Acetamid als Biomarker für periphere Benzodiazepin-Rezeptorverteilung
BR112012014715A2 (pt) 2009-12-18 2018-10-09 Oreal "processo de tratamento cosmético da pele, e, conjunto cosmético"
FR2960773B1 (fr) 2010-06-03 2015-12-11 Oreal Procedes de traitement cosmetique utilisant un revetement a base d'un polymere polyamide-polyether
WO2019113248A1 (en) * 2017-12-07 2019-06-13 The Regents Of The University Of California Anti-upar antibody-drug conjugates and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121137A1 (de) 1981-05-27 1982-12-16 Hoechst Ag, 6000 Frankfurt Neue pyridazino(4,5-b)indole, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen, zwischenprodukte und deren herstellung"
GB9411955D0 (en) * 1994-06-15 1994-08-03 Merck Sharp & Dohme Therapeutic agents
FR2754262B1 (fr) * 1996-10-08 1998-10-30 Synthelabo Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique
US6031120A (en) * 1997-07-29 2000-02-29 E. I. Du Pont De Nemours And Company Selective synthesis of organodiphosphite compounds
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788776B1 (fr) * 1999-01-26 2001-02-23 Synthelabo Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
CN1344161A (zh) 2002-04-10
BG65152B1 (bg) 2007-04-30
PT1148881E (pt) 2006-12-29
NZ512981A (en) 2002-10-25
BR0007718A (pt) 2001-11-13
FR2788696A1 (fr) 2000-07-28
HK1040905B (zh) 2007-02-23
ES2269097T3 (es) 2007-04-01
EP1148881A1 (de) 2001-10-31
NO20013645L (no) 2001-09-26
ATE335487T1 (de) 2006-09-15
CA2360754A1 (en) 2000-08-03
WO2000044384A1 (fr) 2000-08-03
NO321997B1 (no) 2006-07-31
DK1148881T3 (da) 2006-12-11
CN100577167C (zh) 2010-01-06
CZ20012681A3 (cs) 2001-10-17
PL193420B1 (pl) 2007-02-28
KR20010089624A (ko) 2001-10-06
HUP0201280A2 (en) 2002-08-28
KR100694752B1 (ko) 2007-03-14
HK1040905A1 (en) 2002-06-28
UA70349C2 (en) 2004-10-15
US6395729B1 (en) 2002-05-28
SK285707B6 (sk) 2007-06-07
IL144181A (en) 2007-06-17
EE200100388A (et) 2002-12-16
CA2360754C (en) 2008-07-08
SK10502001A3 (sk) 2002-01-07
CY1106257T1 (el) 2011-06-08
EE04905B1 (et) 2007-10-15
CZ294283B6 (cs) 2004-11-10
PL349364A1 (en) 2002-07-15
HU228670B1 (en) 2013-05-28
IL144181A0 (en) 2002-05-23
CO5160242A1 (es) 2002-05-30
NO20013645D0 (no) 2001-07-24
DE60029929T2 (de) 2007-08-30
RU2243764C2 (ru) 2005-01-10
FR2788696B1 (fr) 2004-03-05
AR022413A1 (es) 2002-09-04
EP1148881B1 (de) 2006-08-09
TW541177B (en) 2003-07-11
TR200102134T2 (tr) 2003-03-21
HUP0201280A3 (en) 2004-12-28
JP4688295B2 (ja) 2011-05-25
AU764445B2 (en) 2003-08-21
JP2002535370A (ja) 2002-10-22
AU3057900A (en) 2000-08-18
BG105728A (en) 2002-02-28

Similar Documents

Publication Publication Date Title
DE60029929D1 (de) VERWENDUNG VON PYRIDAZINO i4,5-(b)ö-INDOLE-1-ACETAMIDE DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR BEHANDLUNG VON DURCH PERIPHERE BENZODIAZEPINREZEPTOREN-STÖRUNGEN VERURSACHTE KRANKHEITEN
DE60004974D1 (de) Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE262331T1 (de) Heterocyclische vinylether zur behandlung neurologischer krankheiten
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE59608861D1 (de) Verwendung von N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl]-2,2-diphenyl-acetamid Hydrochlorid zur Herstellung von Arzneimitteln zur Behandlung von entzündlichen Darmerkrankungen
DK0501705T3 (da) Anvendelse af tomoxetin til behandling af sygdomme i de nedre urinveje
DE69910202D1 (de) EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden
IT1318514B1 (it) Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
DE69500673T2 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
DE69423577T2 (de) Verwendung von Oenothein B zur Herstellung eines Medikaments zur Behandlung der durch Hyperandrogenität bedingte Störungen.
DE60128911D1 (de) Verwendung von l-threo-methylphenidat zur herstellung eines medikamentes zur behandlung von psychischen erkrankungen
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
ATE261434T1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69007065T2 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
DE69632677D1 (de) Verwendung eines Rifamycin-Derivates zur Herstellung eines Medikamentes zur Behandlung von Krankheiten verursacht durch Helicobacter pylori-Infektionen
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
ATE253905T1 (de) Verwendung von beta-rezeptorenblocker zur herstellung eines medikaments zur behandlung von krankheiten der äusseren retina
DE69739190D1 (de) Arzneimittel zur behandlung von oculären kreislauferkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition